For clinical development and commercialization of Dr Reddy's Phase III clinical trail candidate
Dr Reddy's Laboratories and CHD Bioscience Inc. has announced a global licensing agreement for the clinical development and commercialization of Dr Reddy's phase III clinical trial candidate, DFA-02. It is intended to be used for the prevention of surgical site infections, following non-emergency, elective colorectal surgery. Phase II studies for DFA-02 have been successful completed and the product will be transitioning to pivotal phase III registration studies.Under the terms of agreement, Dr Reddy's would receive equity in CHD valued at $30 million upon an IPO of CHD or a minimum of $30 million in cash within 18 months of execution of the agreement. Dr Reddy's will also receive additional milestone payments of $40 million up on USFDA approval. In addition, CHD will pay Dr Reddy's double digit royalties on sales and commercial milestones.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
